Cardiol Therapeutics Inc. Stock
A very strong showing by Cardiol Therapeutics Inc. today, with an increase of €0.14 (5.600%) compared to yesterday's price.
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Cardiol Therapeutics Inc. is rather balanced.
With a target price of 3 € there is a slightly positive potential of 17.88% for Cardiol Therapeutics Inc. compared to the current price of 2.55 €.
So far the community has only identified positive things for Cardiol Therapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cardiol Therapeutics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
- Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024
-
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Topline Results Expected in Q2 2024
This is a Designated News Release.
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”),